Delphinus Medical Technologies has raised $12 million in growth capital from Trinity Capital, which it will use to further develop and commercialize its SoftVue 3D whole breast ultrasound tomography system.
The system, which received 510(k) clearance by the U.S. Food and Drug Administration (FDA) in 2021, is meant to serve as an adjunct to digital mammography in the screening of asymptomatic women with dense breast tissue.
SoftVue can identify up to 20% more cancers when paired with screening mammography, while also reducing false positives and decreasing unnecessary call-backs and biopsies, according to Delphinus.
